Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

385.12 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

October 14, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth ↗

September 25, 2026

Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a...

Via MarketBeat

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

September 16, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

August 31, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad (NYSE:BIO) Falls After Q2 Beat as Life Science Sales Weigh ↗

August 04, 2026

Via Chartmill

Bio-Rad Q1 2026 Revenue Misses Estimates, Outlook Cut as NYSE:BIO Faces Cautious Trading ↗

April 30, 2026

Via Chartmill

Bio-Rad Laboratories (NYSE:BIO) Stock Plummets 12% After Q4 Earnings Miss and Weak 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Digital PCR revenue surged over 20% as clinical diagnostics grew.

Via The Motley Fool

Topics Earnings

Bio-Rad Laboratories Q2 Earnings Call Highlights ↗

August 05, 2026

Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral...

Via MarketBeat

Topics Earnings

Bio-Rad Reports Second-Quarter 2026 Financial Results

August 04, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 23, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? ↗

June 22, 2026

Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.

Via The Motley Fool

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories ↗

May 18, 2026

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.

Via Benzinga

Bio-Rad to Participate in Upcoming Investor Conferences

May 08, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad (BIO) Q2 2025 Earnings Call Transcript ↗

May 04, 2026

Bio-Rad (BIO) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Bio-Rad (BIO) Q1 2026 Earnings Transcript ↗

May 01, 2026

Bio-Rad (BIO) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics World Trade

Bio-Rad Reports First-Quarter 2026 Financial Results

April 30, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026

April 16, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad (BIO) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Bio-Rad (BIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

February 12, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

January 29, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

January 06, 2026

From Bio-Rad Laboratories, Inc.

Via Business Wire

Why a Fund Trimmed a $41 Million CompoSecure Stake Amid a 47% Stock Run ↗

December 23, 2025

Amid a monster year and, more recently, a transformative deal announcement, this move raises a sharper question about how much upside is really left at today’s valuation.

Via The Motley Fool

Topics Regulatory Compliance

Why a Fund Cut $4 Million of Payoneer Stock Despite Record Revenues ↗

December 23, 2025

Payoneer just posted record revenue and raised guidance, yet one fund trimmed its stake. The disconnect is where the real story is.

Via The Motley Fool

Topics Regulatory Compliance

Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday ↗

October 30, 2025

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Via The Motley Fool

Topics Supply Chain

Bio-Rad Reports Third-Quarter 2025 Financial Results

October 29, 2025

From Bio-Rad Laboratories, Inc.

Via Business Wire

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

October 16, 2025

From Bio-Rad Laboratories, Inc.

Via Business Wire

Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism

October 01, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away

September 29, 2025

From Bio-Rad Laboratories, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.